B-type natriuretic peptide. A biomarker all the right reasons

Italian Heart Journal

Volumn 5, Issue 6, 2004, Pages 417-420

  Bhalla, Vikas ^a,b   Maisel, Alan S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

BLOOD; CONGESTIVE HEART FAILURE; EDITORIAL; HUMAN; SECRETION; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; SENSITIVITY AND SPECIFICITY;

EID: 6944253834     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. American Heart Association. Heart Disease and stroke statistics - 2003 update. Dallas, TX: American Heart Association, 2002.
2. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-23.
3. Vinson JM, Rich MW, Sperry JC, et al. Early readmission of elderly patients with heart failure. J Am Geriatr Soc 1990; 38: 1290-5.
4. Krumholz HM, Wang Y, Parent EM, Mockalis J, Petrillo M, Radford MJ. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 1997; 157: 99-104.
5. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide (BNP) in the diagnosis of heart failure in an urgent care setting. J Am Coll Cardiol 2001; 37: 379-85.
6. Maisel AS, Krishnaswamy P, Nowak RM, et al, for the Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-7.
7. Morrison L, Harrison A, Krishnaswamy P, et al. Utility of rapid B-type natriuretic peptide in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002; 39: 202-9.
8. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392-7.
9. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001; 345: 1689-97.
10. Chen HH, Burnett JC. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians 1999; 111: 406-16.
11. Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int 1987; 31: 1402-15.
12. Henry JP, Pearce JW. The possible role of cardiac atrial stretch receptors in the induction of changes in urine flow. J Physiol 1956; 131: 572-85.
13. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28: 89-94.
14. Kangawa K, Fukuda A, Kubota I, Hayashi Y, Minamitake Y, Matsuo H. Human atrial natriuretic polypeptides (hANP): purification, structure synthesis and biological activity. J Hypertens Suppl 1984; 2: S321-S323.
15. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332: 78-81.
16. Mukoyama M, Nakao K, Hosada K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-12.
17. Kohno M, Horio T, Yoshiyama M, Takeda T. Accelerated secretion of brain natriuretic peptide from the hypertrophied ventricles in experimental malignant hypertension. Hypertension 1992; 19: 206-11.
18. Yamamoto K, Burnett JC, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28: 988-94.
19. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349-53.
20. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
21. Wieczorek SJ, Wu AH, Christenson R, et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J 2002; 144: 834-9.
22. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-63.
23. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350: 647-54.
24. Atisha D, Bhalla MA, Morrison LK, et al. A prospective study in search of an optimal BNP level to screen patients for cardiac dysfunction. Am Heart J 2004, in press.
25. Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 2004; 43: 1019-26.
26. Kazanagra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 2001; 7: 21-9.
27. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma amino terminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-30.
28. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001; 37: 386-91.
29. Lee SC, Stevens TL, Sandberg SM, et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail 2002; 8: 149-54.